Therefore, it is necessary to monitor both CD33 and NKG2D expression levels on ex vivo expanded NK cells and leukemic blasts isolated from PB of AML patients to improved therapeutic benefit. The gene discussed is KLRK1; the disease is acute myeloid leukemia.